NCT05420909已完成不适用
Overall Survival for Metastatic Colorectal Cancer Patients Matched to CHECKMATE-142
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2019年1月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 124
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
- •Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
- •Pathology consistent with CRC
- •At least two documented clinical visits on or after January 1, 2013
- •Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
- •Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
- •Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
- •Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study
排除标准
- •Participants <18 years of age at index date
- •Participants who received clinical trial drug during the prior or post periods
结局指标
主要结局
Overall Survival (OS)
时间窗: Up to 6 years
Duration of Systemic Treatment
时间窗: Up to 6 years
Durations were reported for the first line of therapy prior to the second line (2L) therapy of interest, the 2L therapy of interest, the third line of therapy, and the at least fourth line of therapy.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study in Second Line Metastatic Colorectal CancerColorectal CancerNCT01183780Eli Lilly and Company1,072
已完成
2 期
A Study of Ramucirumab or Icrucumab in Colorectal CancerRectal CancerColon CancerNCT01111604Eli Lilly and Company158
已完成
不适用
BMI and Lymph Node Count in Colorectal CancerThe Aim of This Study is to Determine the Influence of BMI and Lymph Node Status on OS in CRC Patients in the Long TermNCT06334926Klinikum Floridsdorf1,192
Unknown
不适用
Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal CancerColorectal Cancer MetastaticNCT04543019Assiut University50
已完成
不适用
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life DatabasesMetastatic Breast CancerNCT03676257Institut Bergonié20,033